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Genetic Variability and Extrapolation
from Animals to Man: Some
Perspectives on Susceptibility to
Chemical Carcinogenesis from
Aromatic Amines
by Wendell W. Weber*
I would like to consider the problem of chemical
carcinogenesis arising from exposure to certain aro-
matic amines as a basis for my remarks about the
predictive value for man of data obtained in other
species and biological systems. This example was
chosen because it illustrates the complexity of ex-
trapolation very well, and there is new knowledge
derived from a variety of disciplines including
biochemistry, molecular biology, microbial and
human genetics and pharmacology and from various
levels of biological organization which must be
brought together to enable us to predict the risks to
man from exposure to these environmental agents.
Aromatic amines are one of the principal groups
of chemical carcinogens. They were first discov-
ered to be carcinogenic in man as a result of indus-
trial exposure followed by a 15-20 year latent period.
Aromatic amines which produce tumors in animals
are not in themselves carcinogenic, but they be-
come so after they have been converted in vivo to
more reactive substances. Metabolism of car-
cinogenic arylamines is complex and may include
ring hydroxylation, N-hydroxylation, conjugation
of the ring and N-hydroxyl metabolites, and N-
acylation of the amine function. Deacylation of
N-acylated arylamines is also observed. The major
route for metabolism of carcinogenic arylamines in
many species involves N-acetylation of the amine
group (1).
*Department of Pharmacology, University of Michigan Medi-
cal School, Ann Arbor, Michigan 48109.
The information that I would like to discuss can
be divided into three parts: (1) that which tells us
about the chemical nature of mutagenic and car-
cinogenic metabolites of these amines; (2) that
which has enabled us to test and classify these sub-
stances according to their mutagenic properties and
carcinogenic potential; and (3) that which has pin-
pointed specific individual differences which can
affect metabolic capacity of exposed persons to
generate the ultimate carcinogen(s) and hence alter
their susceptibility to mutagenic and carcinogenic
changes.
Aminofluorene (AF) (Fig. 1) is a well known rep-
resentative aromatic amine which causes tumors in
animals (2). It is also now well established that
N-hydroxy-2-acetylaminofluorene (N-OH-AAF) is
an in vivo metabolite of AF (3), but even this com-
pound is probably not the ultimate carcinogen.
N-Hydroxylation of AAF is catalyzed by a mi-
crosomal oxidative enzyme which involves the
heme-protein catalyst, P1450, or as it is now called,
P448. Reactions of this sort are not unusual, since
most drugs and foreign substances are extensively
metabolized by the body before they are eliminated
by oxidation, reduction, or hydrolysis, or by conju-
gation to form acetyl, glucuronide, or sulfate de-
rivatives. In fact, many foreign substances are
metabolized by more than one of these reactions
either simultaneously or consecutively. Generally
speaking, these transformations are catalyzed by
special enzymes in the liver and other tissues ofthe
body, and they are subject to variation on a heredi-
tary basis. Because ofthe marked variation that oc-
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FIGURE 1. Metabolic activation ofdangerous amines.
curs between different animals and man, no one
species can serve as a model for the metabolism for
any foreign compound in all humans, nor does any
single species exactly mimic the metabolism of all
drugs in any individual (4). It must also be kept in
mind that the levels of activities of these drug
metabolizing enzymes are generally inducible by
phenobarbital and with specificity by some hy-
drocarbons (e.g., 3-methylcholanthrene), and they
are modulated by a variety of other environmental
factors including drugs and diet. The extent of en-
zyme induction may also be genetically regulated
(5).
Within the past few years the patterns of
metabolism of numerous hydrophobic substrates
including various carcinogenic and toxic exogenous
chemicals have been examined after exposure to
different enzyme inducers in an experimental
mouse genetics model. Variations in the patterns of
metabolism have been identified with variation in
the genetic expression of cytochrome P448 forma-
tion (6). In early work with this mouse genetics
model, Nebert and his colleagues showed that the
induction of aryl hydrocarbon hydroxylase activity
and the formation of new cytochrome P448 both
display Mendelian inheritance as an autosomal
dominant and are genetically coregulated in that
species. Recently, they have extended these findings
in this system to several known carcinogens, includ-
ing AAF (7). These studies are especially pertinent
here, because the genetic differences in capacity to
metabolize foreign compounds were combined with
the bacterial mutagenesis assay developed by Ames
(8) to evaluate the metabolic activation of AAF to a
frame-shift mutagen. The metabolic activation pro-
cess ofAAF was found to be inherited in Mendelian
fashion as an autosomal dominant and involved the
same genes as those responsible for aryl hydrocar-
bon hydroxylase activity and the formation of new
cytochrome P448 in the mouse. Thus the mutagenic
effects of AAF appear to be associated with geneti-
cally mediated increases in microsomal oxidative en-
zyme activity associated with a specific cytochrome,
P448.
As data continues to accumulate, it is becoming
clearer that alternate metabolic products may be
formedfrom the same substrate underthe stimulus of
different inducers, presumably because of catalytic
differences in variant forms of the cytochromes in-
duced. In the future, presumably it will be possible,
by use of this experimental genetics model system
in combination with inhibitors which can block al-
ternative inducible pathways selectively, to
evaluate the relative importance of individual path-
ways in augmenting or decreasing mutagenesis as-
sociated with specific agents such as AAF.
Use of the bacterial mutagenesis assay to assess
the metabolic activation of AAF and other hazard-
ous substances (Table 1) is somewhat controversial,
because it involves a kind of double-barreled ex-
Table 1. Assay of amines by the Ames Salmoneila/microsome
test system.a
Amine Mutagenicity Carcinogenicity
2-Aminofluorene ++ +
6-Aminochrysene + +
Proflavin + ?
2-Aminoanthracene ++ +
I-Aminoanthracene + +
a-Naphthylamine + 0
f3-Naphthylamine + +
4-Aminobiphenyl + +
2-Aminobiphenyl + ?
Benzidine + +
Aniline 0 ?
aData of McCann (9).
trapolation. One is the extrapolation from mutant
tester bacterial (Salmonella typhimurium) strains to
eukaryotic mammalian cells. The other is the ex-
trapolation from mutagenesis to carcinogenesis.
Evidence is accumulating, much of it obtained with
this test, that there is a high correlation between
carcinogenicity and mutagenicity: 90%o (156/174) of
carcinogens tested were found to be mutagenic. In
addition, 46 common biochemicals that are noncar-
cinogens, or presumed noncarcinogens, have been
tested and found negative (9). On the other hand,
many carcinogens have been suggested to be non-
mutagenic, making it seem that there was no neces-
sary relationship between carcinogenicity and
mutagenicity (10). This apparent discrepancy has
been reduced by the discovery of metabolic activa-
tion in vivo, which has provided strong support for
somatic mutagenesis as an attractive hypothesis to
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cancer prevention from chemical carcinogens re-
quires simple, rapid and inexpensive screening
methods as complements to expensive, long-term
animal tests to identify dangerous chemicals and the
Salmonella/microsome test is an elegant approach
which satisfies these requirements. The utility and
limitations of this test and other tests which are
similar in principle but use tester strains ofmamma-
lian cells (11) for detecting chemicals likely to be
environmental mutagens or carcinogens for humans
is continuing.
Inspection of the pathway for metabolic activa-
tion of AF in Figure 1 indicates several other po-
tential sites for genetic variation. Clearly, the
capacity for deacetylation is enzymatically
mediated and subject to genetic variability which
could alter the rate offormation of an ultimate car-
cinogen. A similar comment can be made about the
sulfation of AAF which is mediated by a sulfo-
transferase. Very little appears to have been re-
ported about the range of variability of either of
these activating reactions.
The initial step in the activation ofAF is acetyla-
tion of the aromatic amine group. A genetic
polymorphism in the acetylation of drugs which
contain either an aromatic amine or a hydrazine
group has been known since its recognition by
Hughes more than twenty years ago in studies of
patients experiencing chronic toxicity from
isoniazid (12). Genetic studies in human families
(13, 14) showed that persons could be classified into
two major genetic subgroups, termed rapid and
slow isoniazid acetylators (Fig. 2). Acetylation of
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FIGURE 2. Bimodal distribution of plasma isoniazid concentra-
tions (14).
isoniazid is controlled by two autosomal allelic
genes, and slow acetylators are homozygous for the
slow recessive gene. Differences in the rate of
acetylation of isoniazid are attributable to different
amounts of drug acetylating enzyme (N-acetyl-
transferase) in liver. A genetic polymorphism of a
similar sort also exists in rabbits and the rate of
elimination ofisoniazid by acetylation is highly cor-
related in both species with the amount of isoniazid
N-acetyltransferase in liver.
There are several drugs in wide medical use today
which must undergo acetylation prior to their elimi-
nation. The rate of acetylation of some of these
drugs is controlled mainly by the same genes as that
for isoniazid while the rate ofacetylation of several
others is not (Table 2). Our laboratory has been
interested in obtaining information about the basis
Table 2. Drugs inactivated by acetylation in man and rabbit.
I. Drug substrates for polymorphic (isoniazid)
liver N-acetyltransferase
Isoniazid
Sulfamethazine
Hydralazine
Diaminodiphenylsulfone
Sulfapyridine
Procainamide
II. Drugs acetylated mainly by other N-acetyltransferases
p-Aminobenzoic acid (PABA)
p-Aminosalicylic acid
Sulfanilamide
ofthis genetic traitand its consequences forman for
several years (15). Thus, it was of interest to us to
ask whether the rate of acetylation of any of the
mutagenic and carcinogenic amines might be sub-
ject to variation in the same way as isoniazid and
we devised a simple screening test to test this
hypothesis. The test involves the determination of
the rate of acetylation ofthe hazardous amine with
liver homogenates prepared from rapid and slow
acetylator rabbits, and comparison with the rates of
acetylation of our standard "polymorphic" sub-
strate, sulfamethazine, and our standard
"monomorphic" substrate, p-aminobenzoic acid.
Our findings show that aminofluorene resembles
sulfamethazine, and thus behaves as a "polymor-
phic" substrate like isoniazid in this system (Table
3). Other amines selected from the list ofmutagenic
and carcinogenic amines (9) which we have tested in
this system are benzidine, a-naphthylamine, and
,8-naphthylamine, and they also are "polymorphic"
substrates (16).
Thus, it appears that individuals that are geneti-
cally rapid acetylators of isoniazid might also be
expected to transform AF and other hazardous
amines to activated carcinogenic forms more
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iHver N-acetyl transferase.a
Amine substrate KMi M R Rate/S Rate b
Sulfamethazine 4.4 x 104 287: 1
p-Aminobenzoic acid 6.9 x 10o- 7: 1
a-Naphthylamine 8.2 x 10- 539: 1
f3-Naphthylamine 4.1 x l0- 312: 1
2-Aminofluorene 8.0 x 106 579: I
Benzidine 6.0 x 10-6 555 : 1
a[AcCoA] = 5 x 10-4 M.
bR= rapid INH acetylator; S = slow INH acetylator.
rapidly than slow acetylators. These observations
should be confirmed with enzyme preparations
from rapid and slow human liver before they can be
taken as conclusive, and we are currently continu-
ing our assessment ofthe possible role ofthis genetic
polymorphism as a human determinant of suscepti-
bility to chemical carcinogenesis from dangerous
aromatic amines.*
*Subsequent investigations with homogenates of human liver
N-acetyltransferase obtained from rapid and slow acetylators
have confirmed these findings for man. These results will be the
subject of a more detailed report to be published elsewhere.
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